Navigation Links
InterMune Announces Progress on Pirfenidone in IPF
Date:4/21/2008

epatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
2. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
3. InterMune Announces Start of Phase 1b Trial of ITMN-191
4. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Aida Announces New Anti-Cancer Drug Under Development
7. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. ViroPharma Announces Discontinuation of HCV-796 Development
11. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Research and Markets has announced ... Packaging Industry Report 2014" report to their offering. ... The Global and Chinese Aseptic Packaging Industry Report is ... of the global Aseptic Packaging industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that ... research imaging system market will be significantly driven ... combining computed tomography and magnetic resonance imaging with ... from the need for higher-quality imaging to satisfy ... will spur preclinical imaging system sales. ...
(Date:7/30/2014)... 2014   Unique Pizza and Subs Corporation ... UPZS), a Delaware Corporation, is pleased to announce ... Pharmaceutical Corporation ("Larasan"), a nature-based pharmaceutical company that produces ... US-based Larasan will work with Unique to help ... Larasan,s vast distribution network throughout China ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2Growing Popularity of Multimodality Imaging Will Drive the Preclinical Animal Research Imaging System Market 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3
... ASSERT Trial Presented at EULAR, BARCELONA, Spain, ... at the European League Against Rheumatism (EULAR),Annual ... with,ankylosing spondylitis (AS) who received REMICADE(R) (infliximab),over ... In addition, REMICADE-treated patients showed sustained,reductions in ...
... Biotech (OMX Nordic: ACTI) presented,pre-clinical results for ... (The,European League Against Rheumatism, <a target="_blank" href=,"http://www.eular.org/">www.eular.org ... pre-clinical data presented show that I-3D has ... an,experimental model for rheumatoid arthritis (RA)", commented ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... 2014 The study, The Truth ... Medicare episode of care payments for four clinical areas—congestive ... joint replacements (hips and knees). Using the definition ... for Care Improvement program, the study examines these clinical ... in the country. , “Our study reaffirms that, in ...
(Date:7/30/2014)... The Mesothelioma Applied Research Foundation ... Center, will host a regional conference on ... field of mesothelioma. September 26 marks the National Mesothelioma ... the public, and specifically aimed at mesothelioma patients, family ... exposed to asbestos. , The conference will take place ...
(Date:7/30/2014)... Regardless of traumatic events experienced during deployment, returning ... a drinking problem if faced with civilian life ... serious financial and legal problemsall commonplace in military ... Columbia University,s Mailman School of Public Health are ... Preventive Medicine . , Alcohol abuse is a ...
(Date:7/30/2014)... “United States Orthopedic Braces and Supports Market Outlook to 2020?, ... and Supports market. The report provides value, in millions of ... (in US dollars), within market categories:, ... Supports , Spinal Braces and Supports , ... is a specialty within the medical field concerned with the ...
Breaking Medicine News(10 mins):Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:Vets' alcohol problems linked to stress on the home front 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4
... Healthcare and personal care items shipped to QualComm Stadium and other ... for distribution to evacuees, Prescription delivery service from CVS to Qualcomm ... ... filled, WOONSOCKET, R.I., Oct. 24 CVS/pharmacy, the retail,division of CVS Caremark ...
... good to eat," they,re hoping for candy -- and ... but also a tradition that causes,concern about the effects ... and common sense, however, parents can help protect their ... of sugar in Halloween candy is stunning," said Dr. ...
... early gained some symptom relief, study found , , WEDNESDAY, ... month,s worth of inhaler medicine may have lessened rescue ... 11, 2001, World Trade Center attacks, according to new ... anti-inflammatory medicines commonly used for the treatment of asthma. ...
... Washington, D.C.More than three quarters of adults living in ... factor for stroke, but those who are poor do ... wealthier counterparts. In an effort to address these disparities ... NIH,s National Institute of Neurological Disorders and Stroke (NINDS) ...
... advice in approaching decisions about life, career, having a ... of the Institute for Operations Research and the Management ... Research Professor of Decision Sciences at the Fuqua School ... A Practical Guide to Making Better Decisions, a Harvard ...
... messages from meaningless noise could be an early sign ... of Medicine researchers. , The study this month in ... diagnosed with prodromal symptoms meaning they exhibited early warning ... alterations, or misinterpretation of social cues. , Participants in ...
Cached Medicine News:Health News:CVS/pharmacy Donates More Than $300,000 in Supplies to Aid Fire Relief Efforts in California 2Health News:Parents: With Halloween Candy, Focus on Choice and Time to Prevent Teeth Decay 2Health News:Inhaler Eased Lung Problems in 9/11 Workers 2Health News:Inhaler Eased Lung Problems in 9/11 Workers 3Health News:Georgetown leads major effort to combat disparities in DC stroke care 2Health News:Georgetown leads major effort to combat disparities in DC stroke care 3Health News:Trouble deciding? 2Health News:Trouble deciding? 3
... System provides anterior column support for single ... T1 to L5. The system consists of ... cages that are stacked to a desired ... Carbon Fiber Reinforced Polymer material emulates the ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... Cage system is a carbon fiber reinforced ... and biologic functions of posterior lumbar interbody ... provides a device designed to meet the ... cancellous bone, the best possible bone for ...
... is highly adaptable and therefore suitable for ... to its extraordinary small outer diameter and ... of a simple but secure and reliable ... steering instruments around the corner. These characteristics ...
Medicine Products: